Statera BioPharma Inc STAB Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.00 unchanged at close Nov 6
Last close · Previous close $0.00
- Market cap
- $6.42KAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$2.38Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.00up $0.00, 100.00%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.00Nov 5
- Volume2.97KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume38.43KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.00 to $0.03; now $0.00
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
STAB beat the S&P 500 in 3 of 7 periods.
| Period | STAB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | STAB: up 100.0% S&P 500: down 5.6% | STAB beat the S&P 500 by 105.6 percentage points Beat |
| 3M | STAB: unchanged S&P 500: down 4.1% | STAB beat the S&P 500 by 4.1 percentage points Beat |
| YTD | STAB: down 33.3% S&P 500: up 8.7% | STAB trailed the S&P 500 by 42.0 percentage points Trailed |
| 1Y | STAB: up 100.0% S&P 500: up 10.9% | STAB beat the S&P 500 by 89.1 percentage points Beat |
| Long term | ||
| 3Y | STAB: down 98.0% S&P 500: up 75.0% −72.9% vs +20.5% a year | STAB trailed the S&P 500 by 173.0 percentage points Trailed |
| 5Y | STAB: down 100.0% S&P 500: up 67.8% −86.0% vs +10.9% a year | STAB trailed the S&P 500 by 167.8 percentage points Trailed |
| 10Y | STAB: down 100.0% S&P 500: up 313.1% −59.0% vs +15.2% a year | STAB trailed the S&P 500 by 413.1 percentage points Trailed |
$10,000 invested in STAB 10 years ago (Nov 4, 2016) would be worth about $1 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
STAB beat the S&P 500 in 3 of 7 periods.
| Period | STAB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | STAB: up 100.0% S&P 500: down 5.6% | STAB beat the S&P 500 by 105.6 percentage points Beat |
| 3M | STAB: unchanged S&P 500: down 4.3% | STAB beat the S&P 500 by 4.3 percentage points Beat |
| YTD | STAB: down 33.3% S&P 500: up 7.8% | STAB trailed the S&P 500 by 41.1 percentage points Trailed |
| 1Y | STAB: up 100.0% S&P 500: up 9.7% | STAB beat the S&P 500 by 90.3 percentage points Beat |
| Long term | ||
| 3Y | STAB: down 98.0% S&P 500: up 68.8% −72.9% vs +19.1% a year | STAB trailed the S&P 500 by 166.8 percentage points Trailed |
| 5Y | STAB: down 100.0% S&P 500: up 56.9% −86.0% vs +9.4% a year | STAB trailed the S&P 500 by 156.9 percentage points Trailed |
| 10Y | STAB: down 100.0% S&P 500: up 252.6% −59.0% vs +13.4% a year | STAB trailed the S&P 500 by 352.6 percentage points Trailed |
$10,000 invested in STAB 10 years ago (Nov 4, 2016) would be worth about $1 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$273.60
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Jul 25, 2006.
Stock splits
1
1-for-20 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2022). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$2.38 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 0.0×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - −201,962.58%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $6.91MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Sep 30, 2022 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own STAB DCF in Excel. Value Statera BioPharma with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY22, the quarter ended Sep 30, 2022. “Last 12 months” means the four quarters from Oct 1, 2021 to Sep 30, 2022, and balance-sheet figures are as of Sep 30, 2022.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $3.69Mup 1,459.1%
- Net income
- −$91.83M
- Diluted EPS
- −$2.38
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY20 (Dec 31, 2020) | $0.00 | −$4.23M | −$0.53 |
| Q1 FY21 (Mar 31, 2021) | $0.00 | −$5.29M | −$0.22 |
| Q2 FY21 (Jun 30, 2021) | $0.00 | −$6.61M | −$0.27 |
| Q3 FY21 (Sep 30, 2021) | $236.52K | −$12.72M | −$0.47 |
| Q4 FY21 (Dec 31, 2021) | $1.25M | −$77.24M | −$2.04 |
| Q1 FY22 (Mar 31, 2022) | $997.84K | −$7.76M | −$0.20 |
| Q2 FY22 (Jun 30, 2022) | $768.83K | −$3.49M | −$0.07 |
| Q3 FY22 (Sep 30, 2022) | $670.47K | −$3.35M | −$0.07 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $0.00 | −$12.09M | −$1.66 |
| FY21 (Dec 31, 2021) | $1.49M | −$101.85M | −$2.90 |
Margins
- Gross 70.3%
- Operating −2,391.7%
- Net −2,490.3%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$12.96MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$12.86MLast 12 months
- Capital spending$103.37KLast 12 months
- −351.6%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $8.06MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $506.10KAs of Sep 30, 2022
Cash plus short- and long-term marketable securities on the Sep 30, 2022 balance sheet.
- Total debt$7.41MAs of Sep 30, 2022
- Net debt$6.90MAs of Sep 30, 2022
- 0.05As of Sep 30, 2022
Current assets divided by current liabilities on the Sep 30, 2022 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- −602.5%Last 12 months
Over the last 12 months, Statera BioPharma’s net loss was 602.5% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Statera BioPharma Inc
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Cleveland BioLabs' proprietary platform of Toll-like immune receptor activators addresses conditions such as radiation sickness and cancer treatment side effects. Cleveland Biolabs' most advanced product candidate, Entolimod is being developed as a medical radiation countermeasure for preventing death from acute radiation syndrome and, through its joint venture with Everon Biosciences, LLC - Genome Protection, Inc. - for other anticancer and antiaging indications. Additionally, Cleveland BioLabs also conducts business in the Russian Federation through a joint venture with Joint Stock Company RUSNANO, Panacela Labs, Inc. Cleveland BioLabs maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Colorado, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
STAB news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
STAB stock FAQ
What is STAB stock’s price today?
Statera BioPharma (STAB) traded at $0.00 at the close on , unchanged from the previous close of $0.00. Over the past 52 weeks it has traded between $0.00 and $0.03.
If you invested $1,000 in STAB 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in STAB on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $0 if invested five years ago, $2,000 if invested one year ago, and $0 if invested 20 years ago. Past performance doesn’t predict future returns.
What is Statera BioPharma’s market cap?
Statera BioPharma’s market capitalization is about $6.4 thousand. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.00 (how market cap works). Statera BioPharma reported 32.10M shares outstanding at the end of its latest quarter ().
What is STAB’s P/E ratio?
STAB’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$2.38).
How much revenue does Statera BioPharma make?
Statera BioPharma reported $3.7 million of revenue over the four quarters to , up 1,459.1% from the twelve months before. In its latest quarter (Q3 FY22, ended ) revenue was $670.5 thousand, up 183.5% from a year earlier.
Is Statera BioPharma profitable?
Not over the four quarters to . Statera BioPharma reported a net loss of $91.8 million across those four quarters on $3.7 million of revenue.
What are STAB’s earnings per share?
STAB’s diluted earnings per share were −$2.38 over the four quarters to , compared with −$1.49 in the twelve months before. The latest quarter (Q3 FY22) brought −$0.07 per share, against −$0.47 a year earlier (how EPS works).
Does STAB pay a dividend?
Statera BioPharma hasn’t paid a dividend in the last twelve months.
What is STAB’s 52-week high and low?
Over the past 52 weeks STAB has traded as low as $0.00 and as high as $0.03. At $0.00 at the close on , it is 99.2% below that high and 19,900.0% above the low.
What is STAB’s all-time high?
STAB’s highest closing price was $273.60 on , adjusted for stock splits. At $0.00 at the close on , it is 100.0% below that record.
Has STAB stock ever split?
Yes, once: 1-for-20 on .
How has STAB stock performed?
Including dividends and measured to the close on , STAB has returned −33.3% so far this year and +100.0% over the past year, and −100.0% over five years (−86.0% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Statera BioPharma in?
Statera BioPharma is in the Healthcare sector and the Biotechnology industry, and is headquartered in Colorado, USA.
What exchange does STAB trade on?
Statera BioPharma trades on the PINK under the ticker symbol STAB. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.